Epimmune Incorporated

Epimmune's core business is the development of vaccines to treat and prevent infectious diseases and cancer. Epimmune's business also includes a therapeutic anti-inflammatory program based on cell adhesion inhibitors and its Glytec business unit, encompassing proprietary manufacturing technology for the enzymatic synthesis of bioactive complex carbohydrates.

Contact Details: 5820 Nancy Ridge Drive San Diego CA 92121 United States of America Tel: 858 860 2500 Fax: 858 860 2600 Email: WWW: www.epimmune.com/

Loading...

Recent Publications by Epimmune Incorporated:
Measurement of MHC/peptide interactions by gel filtration. This unit describes a technique for the direct and quantitative...	6th June, 2008	Epimmune Incorporated, San Diego, California, USA.	Curr Protoc Immunol. 2001 May;Chapter 18:Unit 18.3. DOI Direct Link
Formulation and Characterization of a Ten-peptide Single-vial Vaccine, EP-2101, Designed to Induce Cytotoxic T-lymphocyte Responses for Cancer Immunotherapy. Effective vaccines that mediate clinical responses in cancer patients may...	3rd April, 2008	Pharmexa-Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA	Hum Vaccin. 2007 Nov 11;4(3).
Rationally engineered therapeutic proteins with reduced immunogenicity. Chronic administration of protein therapeutics may elicit unacceptable...	29th April, 2005	Epimmune, San Diego, CA 92121, USA.	J Immunol. 2005 Mar 15;174(6):3187-96.
Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. Recognition by CD8(+) T lymphocytes (CTL) of epitopes that are derived...	4th November, 2004	Epimmune, San Diego, CA 92121, USA.	J Immunol. 2004 Aug 1;173(3):1941-50.
Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Experimental carbohydrate-conjugate vaccines composed of the 13 amino acid...	8th September, 2004	Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA 92121,	Vaccine. 2004 Jun 23;22(19):2362-7. DOI Direct Link
→View more Epimmune Incorporated research publications.

Epimmune Incorporated Clinical Trials:
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

Epimmune Incorporated Patents:
US Patent No.	Title
7026443	Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
6322789	HLA-restricted hepatitis B virus CTL epitopes
6413517	Identification of broadly reactive DR restricted epitopes
6413935	Induction of immune response against desired determinants
6419931	Compositions and methods for eliciting CTL immunity
→View more Epimmune Incorporated patents.

Epimmune Incorporated (EPMN) Financial information Links from Barchart
EPMN Quote from from Barchart.com
EPMN Chart from from Barchart.com
EPMN Profile from from Barchart.com
EPMN Opinion from from Barchart.com
→View more Epimmune Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 542 times since April 2007, the link to the organisation's website has been followed 154 times

Recent Search Terms used to find this page: epimmune san diego | epimmune 2009 | epimmune | EPIMMUNE | Epimmune | epimmune | Epimmune | epimmune inc 2009 | epimmune | Epimmune San Diego Ca | .

Search for more companies in San Diego

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Epimmune Incorporated